natgillin/translations-raw huggingface dataset:
valproate (an antiepileptic medicine),
valproat (zdravilo proti epilepsiji)
valproate - a medicine for epilepsy
valproat – zdravilo za epilepsijo
Valproate: ↓
Vorikonazol
Valproic acid
valprojska kislina
valproic acid (an antiepileptic drug),
valprojsko kislino (zdravilo proti epilepsiji)
Valproic acid (medicine used to treat epilepsy)
valprojska kislina (zdravilo za zdravljenje epilepsije)
valproic acid or sodium valproate (used to treat epilepsy, bipolar disorder, migraines or schizophrenia)
valprojsko kislino ali natrijev valproat (uporablja se za zdravljenje epilepsije, bipolarne motnje, migren ali shizofrenije)
valproic acid, valproate or carbamazepine, medicines to treat some forms of epilepsy, the varicella vaccine, a medicine used to prevent chickenpox or shingles, within 6 weeks of taking Clopidogrel/Acetylsalicylic acid Zentiva, or if you have active chickenpox or shingles infection (see section 2 ‘Children and adolescents’),
valprojska kislina, valproat ali karbamazepin, zdravila za zdravljenje nekaterih oblik epilepsije, cepivo proti noricam, ki preprečuje nastanek noric ali pasastega izpuščaja, 6 tednov po zaužitju zdravila Klopidogrel/acetilsalicilna kislina Zentiva, ali med okužbo z noricami ali s pasatim izpuščajem (glejte poglavje 2 “Otroci in mladostniki”),
valproic acid, valproate or carbamazepine, medicines to treat some forms of epilepsy, the varicella vaccine, a medicine used to prevent chickenpox or shingles, within 6 weeks of taking DuoPlavin, or if you have active chickenpox or shingles infection (see section 2 ‘Children and adolescents’),
valprojska kislina, valproat ali karbamazepin, zdravila za zdravljenje nekaterih oblik epilepsije, cepivo proti noricam, ki preprečuje nastanek noric ali pasastega izpuščaja, 6 tednov po zaužitju zdravila DuoPlavin, ali med okužbo z noricami ali s pasatim izpuščajem (glejte poglavje 2 “Otroci in mladostniki”),
valproic acid, valpromide or carbamazepine – to treat fits (seizures), mood disorders and prevent migraines
valprojska kislina, valpromid ali karbamazepin – za zdravljenje napadov krčev (konvulzij), motenj razpoloženja in preprečevanje migrene
Valproic acid/Emtricitabine
valprojska kislina/dizoproksiltenofovirijev fumarat
valproic acid: a medicine to treat epilepsy and mental disorders
valprojska kislina: zdravilo za zdravljenje epilepsije in duševnih motenj,
Valsartan
pogostnost neznana
valsartan (for hypertension); repaglinide (for diabetes).
valsartan (za povišan krvni tlak), repaglinid (za sladkorno bolezen).
Valsartan and
valsartan in hidrokloro- tiazid
Valsartan and HCT
valsartan in hidrokloro- tiazid
valsartan and olmesartan (used to treat high blood pressure);
valsartan in olmesartan (uporabljata se za zdravljenje visokega krvnega tlaka);
Valsartan is an ‘angiotensin II receptor antagonist’, which means that it blocks the action of a body hormone called angiotensin II.
Valsartan je antagonist receptorja angiotenzina II, kar pomeni, da zavira delovanje telesnega hormona, imenovanega angiotenzin II.
Valsartan is an ‘angiotensin II receptor antagonist’, which means that it blocks the action of a body hormone called angiotensin II.
Valsartan je antagonist receptorja za angiotenzin II, kar pomeni, da zavira delovanje telesnega hormona, imenovanega angiotenzin II.
Valsartan is an ‘angiotensin II receptor antagonist’, which means that it blocks the action of a hormone in the body called angiotensin II.
Valsartan je antagonist receptorja za angiotenzin II, kar pomeni, da zavira delovanje telesnega hormona, imenovanega angiotenzin II.
Valsartan is an ‘angiotensin II receptor antagonist’, which means that it blocks the action of a hormone in the body called angiotensin II.
Valsartan je „antagonist receptorja za angiotenzin II“, kar pomeni, da zavira delovanje telesnega hormona, imenovanega angiotenzin II.
Valsartan is an ‘angiotensin-II-receptor antagonist’, which means that it blocks the action of a hormone called angiotensin II.
Valsartan je "antagonist receptorjev za angiotenzin II", kar pomeni, da v telesu preprečuje delovanje hormona, imenovanega angiotenzin II.
Valsartan is an ‘angiotensin-II-receptor antagonist’, which means that it blocks the action of a hormone called angiotensin II.
Valsartan je „antagonist receptorjev za angiotenzin II“, kar pomeni, da v telesu preprečuje delovanje hormona, imenovanega angiotenzin II.
Valsartan is highly bound to serum proteins (94–97 %), mainly serum albumin.
Valsartan je močno vezan na beljakovine v serumu (94-97%), predvsem na albumin v serumu.
Valsartan is highly bound to serum proteins (94–97%), mainly serum albumin.
Valsartan je močno vezan na beljakovine v serumu (94-97 %), predvsem na albumin v serumu.
Valsartan is primarily eliminated in faeces (about 83 % of dose) and urine (about 13 % of dose), mainly as unchanged drug.
Valsartan se v prvi vrsti izloči v blato (okrog 83% odmerka) in urinu (okrog 13% odmerka), v glavnem v obliki nespremenjenega zdravila.
Valsartan is unlikely to be removed by haemodialysis.
Ni verjetno, da bi valsartan odstranili z dializo.
Valsartan Potassium-sparing
Valsartan diuretiki, ki varčujejo s
Valtropin 5 mg/1.5 ml powder and solvent for solution for injection
Valtropin 5 mg/1,5 ml prašek in vehikel za raztopino za injiciranje
Valtropin 5 mg/1.5 ml powder and solvent for solution for injection somatropin
Valtropin 5 mg/1,5 ml prašek in vehikel za raztopino za injiciranje somatropin
Valtropin 5 mg/1.5 ml powder for solution for injection somatropin
Valtropin 5 mg/1,5 ml prašek za raztopino za injiciranje somatropin
Valtropin can affect the amount of thyroid hormone in the blood, so you must have thyroid function tests from time to time.
Zdravilo Valtropin lahko vpliva na količino hormonov ščitnice v krvi, zato morate občasno opraviti preizkuse delovanja ščitnice.
Valtropin has no or negligible effect on the ability to drive and use machines.
Zdravilo Valtropin nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Valtropin is a ‘biosimilar’ medicine.
Zdravilo Valtropin je podobno biološko zdravilo.
Valtropin is given by injection under the skin, once a day.
Zdravilo Valtropin se daje z injekcijo pod kožo, enkrat na dan.
Valtropin is used to treat children (2 to 11 years old) and teenagers (12 to 18 years old) who do not develop to their normal height because of poor bone growth caused by growth hormone deficiency (relative lack of growth hormone), Turner syndrome, or ‘chronic renal insufficiency’ (a condition in which the kidneys gradually lose their ability to perform their normal functions, such as the removal of wastes and extra fluid from the body). to treat adults with severe growth hormone deficiency who already had growth hormone deficiency when they were children or who do not have enough growth hormone during their adult years for some other reason.
Zdravilo Valtropin se uporablja: za zdravljenje otrok (starih 2 do 11 let) in mladostnikov (starih 12 do 18 let), ki se niso razvili do normalne višine zaradi slabe rasti kosti, ki jo je povzročilo pomanjkanje rastnega hormona (relativno pomanjkanje rastnega hormona), Turnerjev sindrom ali "kronična ledvična insuficienca" (bolezen, pri kateri ledvice postopno zgubljajo sposobnost normalnega delovanja, kot je odstranjevanje odpadnih snovi in odvečne tekočine iz telesa); za zdravljenje odraslih s hudim pomanjkanjem rastnega hormona, ki so to pomanjkanje imeli že v otroštvu ali ki v odrasli dobi nimajo dovolj rastnega hormona.
Valtropin is used to treat children in the following situations:
Zdravilo Valtropin se uporablja za zdravljenje otrok v naslednjih primerih:
Valtropin may affect the way your body handles sugar from food and drink.
Zdravilo Valtropin lahko vpliva na to, kako vaše telo presnavlja sladkor, ki ga zaužijete s hrano in pijačo.
Valtropin should not be used during pregnancy unless clearly necessary.
Zdravila Valtropin ne smete uporabljati med nosečnostjo, razen če je nujno.
Valtropin should not be used for growth promotion in children with closed epiphyses.
Valtropin se ne sme uporabljati za spodbujanje rasti pri otrocih z zaprtimi epifizami.
value
Vrednost LVEF
Value 2
vrednost 2
Value2
Vrednost2
Values in parentheses correspond to 25 months median observation time (primary analysis).
Vrednosti v oklepajih ustrezajo mediani časa opazovanja 25 mesecev (primarna analiza).
Values outside of parentheses correspond to 48 months median observation time (updated analysis).
Vrednosti zunaj oklepajev ustrezajo mediani časa opazovanja 48 mesecev (posodobljena analiza).
Values presented are for IRESSA versus carboplatin/paclitaxel.
Prikazane so vrednosti za zdravilo IRESSA v primerjavi s karboplatinom/paklitakselom.
Values presented are for IRESSA versus placebo.
Prikazane so vrednosti za zdravilo IRESSA v primerjavi s placebom.
vancomycin (for bacterial infection)
vankomicin (za bakterijsko okužbo)
vancomycin (for bacterial infection).
vankomicin (za bakterijsko okužbo).
vancomycin and aminoglycosides, used for bacterial infections amphotericin B, for fungal infections
vankomicin in aminoglikozidi, ki se uporabljajo proti bakterijskim okužbam; amfotericin B proti glivičnim okužbam;
Vanda Pharmaceuticals Ltd.
Združeno kraljestvo Vanda Pharmaceuticals Ltd.
vandetanib 300 mg, ------ placebo, y-axis=PFS, x-axis=time in months, n-vandetanib=number of patients at risk-vandetanib, n-placebo=number of patients at risk-placebo
vandetanib 300 mg, ------ placebo, y-os=PFS, x-os=čas v mesecih, n-vandetanib=število bolnikov s tveganjem-vandetanib, n-placebo=število bolnikov s tveganjem-placebo
Vandetanib also blocks the activity of RET receptors, which play a role in the growth of medullary thyroid cancer cells.
Vandetanib prepreči tudi aktivnost receptorjev RET, ki sodelujejo pri rasti celic medularnega raka ščitnice.
Vandetanib and/or its metabolites is excreted into milk in rats and found in plasma of pups following dosing to lactating rats (see section 5.3).
Vandetanib in/ali njegovi presnovki se izločajo v mleko podgan in so jih, po uporabi pri doječih podganah, ugotovili v plazmi mladičev (glejte poglavje 5.3).
Vandetanib at a dose of 300 mg is associated with a substantial and concentration dependent prolongation in QTc (mean 28 msec, median 35 msec).
Vandetanib v odmerku 300 mg je povezan z znatnim, od koncentracije odvisnim podaljšanjem intervala QTc (v povprečju za 28 ms, mediana 35 ms).
Vandetanib has been shown to prolong the ECG QTc interval; Torsades de pointes have been uncommonly reported.
Ugotovljeno je, da vandetanib podaljša interval QTc; občasno so poročali o Torsades de pointes.
Vandetanib has shown no carcinogenic potential in a transgenic mouse carcinogenicity study.
V študiji kancerogenosti pri transgenih miših vandetanib ni pokazal kancerogenega potenciala.
Vandetanib is a potent inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2 also known as kinase insert domain containing receptor [KDR]), epidermal growth factor receptor (EGFR) and RET tyrosine kinases.
Vandetanib je močan zaviralec VEGFR-2 (vascular endothelial growth factor receptor-2 – receptor-2 žilnega endotelijskega rastnega dejavnika, znan tudi kot KDR [kinase insert domain containing receptor]), EGFR (epidermal growth factor receptor – receptor epidermalnega rastnega dejavnika) in RET tirozin-kinaze.
Vandetanib is an inhibitor of the organic cation 2 (OCT2) transporter.
Vandetanib je zaviralec prenašalca, imenovanega organski kationski prenašalec 2 (OCT2 – organic cation transporter 2).
Vandetanib is not recommended for use in patients with hepatic impairment (serum bilirubin greater than 1.5 times upper limit of normal), since there is limited data in patients with hepatic impairment, and safety and efficacy have not been established (see section 4.4).
Vandetaniba ni priporočljivo uporabljati pri bolnikih z okvaro jeter (bilirubin v serumu večji od 1,5-kratnika zgornje normalne meje), ker je podatkov o bolnikih z okvaro jeter malo in varnost ter učinkovitost nista bili dokazani (glejte poglavje 4.4).
Vandetanib is not recommended for use in patients with hepatic impairment (serum bilirubin greater than 1.5 times upper limit of normal), since there is limited data in patients with hepatic impairment, and safety and efficacy have not been established.
Vandetaniba ni priporočljivo uporabljati pri bolnikih z okvaro jeter (bilirubin v serumu večji od 1,5- kratnika zgornje normalne meje), ker je podatkov o bolnikih z okvaro jeter malo in varnost ter učinkovitost nista bili dokazani.
Vandetanib is not recommended for use in patients with moderate or severe renal impairment since there is limited data, and safety and efficacy have not been established (see sections 4.2, 5.1, and 5.2).
Uporaba vandetaniba pri bolnikih z zmerno ali hudo okvaro ledvic ni priporočljiva, saj je na voljo le malo podatkov in učinkovitost ter varnost nista bili dokazani (glejte poglavja 4.2, 5.1 in 5.2).
Vandetanib may be administered until patients with MTC are no longer benefiting from treatment.
Vandetanib se lahko daje vse dokler bolnikom z MTC zdravljenje ne koristi več.
Vandetanib prolongs the QTc interval and can cause Torsades de pointes and sudden death
Vandetanib podaljša interval QTc in lahko sproži Torsades de pointes in nenadno smrt.
Vandetanib should not be given to patients who have a history of Torsades de pointes unless all risk factors that contributed to Torsades have been corrected.
Vandetaniba se ne sme dati bolnikom, ki imajo Torsades de pointes v anamnezi, razen če so odpravljeni vsi dejavniki tveganja, ki so prispevali k Torsades de pointes.
Vandetanib treatment must not be started in patients whose ECG QTc interval is greater than 480 msec.
Zdravljenja z vandetanibom se ne sme začeti pri bolnikih, ki imajo interval QTc daljši od 480 ms.
vanilla flavour (containing p-hydroxybenzoic acid, p-hydroxybenzaldehyde, vanillic acid, vanillin, heliotrope, ethyl vanillin),
aromo vanilije (vsebuje p-hidroksibenzojsko kislino, p-hidroksibenzaldehid, vanilinsko kislino, vanilin, heliotrop, etilvanilin)
Vanilla flavour (contains propylene glycol)
Aroma vanilje (vsebuje propilenglikol)
Vaniqa cream should be applied to the affected area twice daily, at least eight hours apart.
Zdravilo Vaniqa je treba nanesti dvakrat dnevno v vsaj osemurnih presledkih na kožo prizadetega predela.
Vaniqa has no or negligible effects on the ability to drive and use machines.
Zdravilo Vaniqa nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
VANTAVO 70 mg/2800 IU tablets
VANTAVO 70 mg/2.800 i.e. tablete
VANTAVO 70 mg/2800 IU tablets
VANTAVO 70 mg/2.800 i.e. tablete alendronska kislina/holekalciferol
VANTAVO 70 mg/2800 IU tablets Alendronic acid /colecalciferol
VANTAVO 70 mg/2.800 i.e. tablete alendronska kislina/holekalciferol
VANTAVO 70 mg/2800 IU tablets are available as capsule-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘710’ on the other.
VANTAVO 70 mg/2.800 i.e. tablete imajo obliko kapsule, so bele do skoraj bele barve, na eni strani imajo vtisnjen obris kosti, na drugi pa oznako ‘710’.
VANTAVO 70 mg/5600 IU tablets
VANTAVO 70 mg/5.600 i.e. tablete
VANTAVO 70 mg/5600 IU tablets
VANTAVO 70 mg/5.600 i.e. tablete alendronska kislina/holekalciferol
VANTAVO 70 mg/5600 IU tablets Alendronic acid /colecalciferol
VANTAVO 70 mg/5.600 i.e. tablete alendronska kislina/holekalciferol
VANTAVO 70 mg/5600 IU tablets are available as modified rectangle-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘270’ on the other.
VANTAVO 70 mg/5.600 i.e. tablete so pravokotniku podobne oblike, bele do skoraj bele barve, na eni strani imajo vtisnjen obris kosti, na drugi pa oznako ‘270’.
VANTAVO is a combination tablet containing the two active substances alendronate sodium trihydrate and colecalciferol (vitamin D3).
Zdravilo VANTAVO je kombinirana tableta, ki vsebuje dve zdravilni učinkovini, natrijev alendronat trihidrat in holekalciferol (vitamin D3).
VANTAVO is a tablet containing the two active substances, alendronic acid (commonly called alendronate) and colecalciferol known as vitamin D3.
Zdravilo VANTAVO je tableta, ki vsebuje dve zdravilni učinkovini: alendronsko kislino (splošno poimenovano alendronat) in holekalciferol oziroma vitamin D3.
VANTAVO is available in packs containing 2, 4 or 12 tablets.
Zdravilo VANTAVO je na voljo v pakiranjih, ki vsebujejo 2, 4 ali 12 tablet.
VANTAVO is available in packs containing 2, 4, 6 or 12 tablets.
Zdravilo VANTAVO je na voljo v pakiranjih, ki vsebujejo 2, 4, 6 ali 12 tablet.
VANTAVO is indicated for the treatment of postmenopausal osteoporosis in women who are not receiving vitamin D supplementation and are at risk of vitamin D insufficiency.
Zdravilo VANTAVO je indicirano za zdravljenje pomenopavzalne osteoporoze pri ženskah, ki ne prejemajo dodatka vitamina D in imajo tveganje za pomanjkanje vitamina D.
VANTAVO is not recommended for patients with renal impairment where creatinine clearance is less than 35 ml/min, due to lack of experience.
Bolnikom z ledvično okvaro, pri katerih je kreatininski očistek manjši od 35 ml/min, zdravila VANTAVO zaradi pomanjkanja izkušenj ne priporočamo.
VANTAVO may have a moderate influence on the ability to drive and use machines in patients that experience certain adverse reactions (for example blurred vision, dizziness and severe bone muscle or joint pain (see section 4.8)).
Zdravilo VANTAVO ima lahko pri bolnikih, pri katerih se pojavijo določeni neželeni učinki (npr. zamegljen vid, omotica in hude bolečine v kosteh, mišicah ali sklepih (glejte poglavje 4.8)), zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
VANTAVO reduces the risk of vertebral and hip fractures.
Zdravilo VANTAVO zmanjša tveganje za vertebralne zlome in za zlome kolka.
VANTAVO should not be given to children and adolescents less than 18 years of age.
Zdravila VANTAVO se ne sme dajati otrokom in mladostnikom, mlajšim od 18 let.
VANTAVO should not be taken at bedtime or before arising for the day.
Bolnik zdravila VANTAVO ne sme vzeti pred spanjem ali preden zjutraj vstane.
VANTAVO should not be used in children less than 18 years of age because no data are available for the alendronic acid/colecalciferol combination.
Ker podatkov o uporabi kombinacije alendronske kisline/holekalciferola ni na voljo, otroci, mlajši od 18 let, zdravila VANTAVO ne smejo jemati.
VANTAVO should only be swallowed after getting up for the day with a full glass of water (not less than 200 ml).
Bolnik mora zdravilo VANTAVO pogoltniti zjutraj, ko vstane, s polnim kozarcem vode (ne manj kot 200 ml).
Vantavo1 alendronic acid and colecalciferol
Vantavo1 alendronska kislina in holekalciferol
Vantobra 170 mg nebuliser solution
Vantobra 170 mg inhalacijska raztopina za nebulator
Vantobra 170 mg nebuliser solution Tobramycin
Vantobra 170 mg inhalacijska raztopina za nebulator tobramicin
Vantobra has no or negligible influence on the ability to drive and use machines.
Zdravilo Vantobra nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje ali upravljanja s stroji.
Vantobra is a ‘hybrid medicine’.
Zdravilo Vantobra je „hibridno zdravilo“.
Vantobra is available as a nebuliser solution in single-dose containers called ‘ampoules’.
Zdravilo Vantobra je na voljo v obliki raztopine za nebulator v enoodmernih vsebnikih, imenovanih
Vantobra is not expected to affect your ability to drive or use machines.
Ne pričakuje se, da bi zdravilo Vantobra vplivalo na sposobnost vožnje ali upravljanja s stroji.
Vantobra nebuliser solution is provided in a ready-to-use ampoule.
Zdravilo Vantobra inhalacijska raztopina za nebulator je raztopina v ampuli, pripravljena na uporabo.
Vantobra should not be used during pregnancy unless the benefits to the mother outweigh the risks to the foetus or baby.
Zdravilo Vantobra se med nosečnostjo ne sme uporabljati, razen če so koristi za mater večje od možnega tveganja za plod ali otroka.
Vardenafil
almeterol
Vardenafil
Flutikazonpropionat:
Vardenafil (for pulmonary arterial hypertension (PAH), or for getting or keeping an erection)
vardenafil (za zdravljenje pljučne arterijske hipertenzije (PAH) ali za zdravljenje moške impotence),
Vardenafil (saquinavir/ritonavir)
ciklosporin rapamicin (sakvinavir/ritonavir)
Vardenafil 20 mg film-coated tablet potentiated the blood pressure lowering effect of sublingual nitroglycerin (0.4 mg) taken 1 and 4 hours after vardenafil administration to healthy middle aged subjects.
Toda 20-miligramski odmerek vardenafila v filmsko obloženih tabletah je zvečal vpliv nitroglicerina (0,4 mg, sublingvalno) na znižanje krvnega tlaka, ki so ga zdravi moški srednjih let vzeli eno in štiri ure po zaužitju vardenafila.
Vardenafil and its major circulating metabolite (M1) are highly bound to plasma proteins (approximately 95% for vardenafil or M1).
Vardenafil in njegovi glavni presnovek (M1) v obtoku se obsežno vežeta na plazemske beljakovine (približno 95 % vardenafila ali M1).
vardenafil are metabolised by CYP3A4.
se presnavljajo s CYP3A4.
Vardenafil AUC and Cmax in elderly patients (65 years or over) taking vardenafil orodispersible tablets were increased by 31 to 39% and 16 to 21%, respectively, in comparison to patients aged 45 years and below.
Pri starejših bolnikih (65 let in več), ki so jemali orodisperzibilne tablete, ki vsebujejo vardenafil, sta se AUC in Cmax vardenafila povečala od 31 do 39 % oziroma 16 do 21 %, v primerjavi z bolniki starimi 45 let in manj.
Vardenafil AUC and Cmax in elderly patients (65 years or over) taking vardenafil orodispersible tablets were increased by 31 to 39% and 16 to 21%, respectively, in comparison to patients aged 45 years and below.
Pri starejših bolnikih (65 let in več), ki so jemali zdravilo Levitra orodisperzibilne tablete sta se AUC in Cmax vardenafila povečala od 31 do 39 % oziroma 16 do 21%, v primerjavi z bolniki starimi 45 let in manj.
Vardenafil AUC and Cmax in elderly patients (65 years or over) taking vardenafil orodispersible tablets were increased by 31 to 39% and 16 to 21%, respectively, in comparison to patients aged 45 years and below.
Pri starejših bolnikih (65 let in več), ki so jemali zdravilo Vivanza orodisperzibilne tablete sta se AUC in Cmax vardenafila povečala od 31 do 39 % oziroma 16 do 21 %, v primerjavi z bolniki starimi 45 let in manj.
Vardenafil dose adjustment is necessary if moderate or potent CYP 3A4 inhibitors are given concomitantly (see section 4.5).
Odmerek vardenafila je treba prilagoditi, če bolnik sočasno jemlje zmerne ali močne zaviralce CYP3A4 (glejte poglavje 4.5).
Vardenafil dose adjustment might be necessary if moderate CYP 3A4 inhibitors such as erythromycin and clarithromycin, are given concomitantly (see section 4.2 and 4.5).
Med sočasno uporabo zmernih zaviralcev CYP3A4 (npr. eritromicin in klaritromicin), je treba odmerek vardenafila po potrebi prilagoditi (glejte poglavji 4.2 in 4.5).
vardenafil in men older than 75-years due to increased risk of adverse events
vardenafil pri moških, starejših od 75 let, zaradi povečanega tveganja neželenih dogodkov,
Vardenafil in Vivanza film-coated tablets is metabolised predominantly by hepatic metabolism via cytochrome P450 (CYP) isoform 3A4 with some contribution from CYP3A5 and CYP2C isoforms.
Vardenafil iz filmsko obloženih tablet se presnavlja predvsem v jetrih s pomočjo citokroma P450 (CYP), izooblike 3A4, pri čemer nekoliko prispevata tudi izoobliki CYP3A5 in CYP2C.
Vardenafil Increased plasma concentrations of vardenafil (see section 4.4. and 4.5).
Vardenafil Zvišana plazemska koncentracija vardenafila (glejte poglavji 4.4 in 4.5).
Vardenafil Increased plasma concentrations of vardenafil (see sections 4.4 and 4.5)
Vardenafil Večja koncentracija vardenafila v plazmi (glejte poglavji 4.4 in 4.5)
Vardenafil is contraindicated in men older than 75 years old (see section 4.3).
Vardenafil je kontraindiciran pri moških, starejših od 75 let (glejte poglavje 4.3).
Vardenafil is rapidly absorbed after administration of 10 mg orodispersible tablets without water.
Vardenafil se hitro absorbira po zaužitju orodisperzibilne tablete po 10 mg vardenafila brez vode.
Vardenafil is rapidly absorbed after administration of vardenafil 10 mg orodispersible tablets without water.
Vardenafil se hitro absorbira po zaužitju 10-mg orodisperzibilne tablete brez vode.